David Phillips - Meridian Bioscience Independent Director
| VIVODelisted Stock | USD 33.97 0.00 0.00% |
Director
Mr. David C. Phillips serves as Chairman of the Board of the Company, effective September 30, 2018. Mr. Phillips spent 32 years with Arthur Andersen LLP. His service with this firm included several managing partner leadership positions. After retiring from Arthur Andersen in 1994, Mr. Phillips became Chief Executive Officer of Downtown Cincinnati, Inc., which is responsible for economic revitalization of Downtown Cincinnati. Mr. Phillips retired from DCI in 1999 to devote full time to Cincinnati Works, Inc., an organization dedicated to reducing the number of people living below the poverty level by assisting them to strive towards selfsufficiency through work, and his financial consulting services. Mr. Phillips has also served as a director of Cintas Corporationrationration, retiring in 2012, and as a director of Summit Mutual Funds, a registered investment company, through 2009. The Board believes that Mr. Phillips years of service as a certified public accountant and trusted advisor to his clients and business owners, which qualify him as an audit committee financial expert under SEC guidelines, give him significant experience in preparing, auditing, analyzing and evaluating financial statements and dealing with complex accounting and business issues, all of which is valuable to Meridian. since 2018.
| Age | 79 |
| Tenure | 6 years |
| Phone | 513 271 3700 |
| Web | https://www.meridianbioscience.com |
Meridian Bioscience Management Efficiency
The company has return on total asset (ROA) of 0.1035 % which means that it generated a profit of $0.1035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1219 %, meaning that it created $0.1219 on every $100 dollars invested by stockholders. Meridian Bioscience's management efficiency ratios could be used to measure how well Meridian Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 25 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Meridian Bioscience has a current ratio of 3.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Meridian Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Meridian Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Meridian Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Meridian to invest in growth at high rates of return. When we think about Meridian Bioscience's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joseph Bonn | Luxfer Holdings PLC | 71 | |
| Virginia Hepner | National Vision Holdings | 60 | |
| Felix Gernburd | National Vision Holdings | 30 | |
| Sally Chaplain | Dow Inc | 59 | |
| Peng Cheng | Pinduoduo | N/A | |
| Adam Cohn | Luxfer Holdings PLC | N/A | |
| Robert Miller | Dow Inc | 74 | |
| David Nelms | CDW Corp | 57 | |
| Bridget RyanBerman | Asbury Automotive Group | 60 | |
| Richard Davis | Dow Inc | 63 | |
| Philip Maritz | Asbury Automotive Group | 60 | |
| Eva Howell | Dow Inc | 69 | |
| Dennis Reilley | Dow Inc | 62 | |
| Barry Allen | CDW Corp | 69 | |
| James Bell | Dow Inc | 71 | |
| Mark Loughridge | Dow Inc | 62 | |
| Terence Leahy | National Vision Holdings | 59 | |
| Joseph Swedish | CDW Corp | 66 | |
| Heather Cianfrocco | National Vision Holdings | 45 | |
| James Bell | CDW Corp | 69 | |
| Raymond Milchovich | Dow Inc | 66 | |
Management Performance
Meridian Bioscience Leadership Team
Elected by the shareholders, the Meridian Bioscience's board of directors comprises two types of representatives: Meridian Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Meridian. The board's role is to monitor Meridian Bioscience's management team and ensure that shareholders' interests are well served. Meridian Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Meridian Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melissa McCarey, VP HR | ||
| John Kraeutler, Chairman, CEO and Pres | ||
| Lawrence Baldini, Executive VP of Operations and Information Systems | ||
| James Anderson, Independent Director | ||
| Emerson Moser, Sr Counsel | ||
| Lourdes Weltzien, Exec Unit | ||
| Amy Winslow, Executive Vice President and Presidentident and CEO - Magellan | ||
| Susan Rolih, Executive Vice President - Regulatory Affairs and Quality Assurance | ||
| Michael Shaughnessy, Executive Vice President; President of Meridian Diagnostics | ||
| Bryan Baldasare, Chief Accounting Officer | ||
| Robert Ready, Director, Chairman of Compensation Committee, Member of Audit Committee, Member of Nominating Corporate Governance Committee, Chairman of LSI Industries Inc and CEO of LSi Industries Inc | ||
| Eric Rasmussen, Executive Vice President - Corporate Development | ||
| Tony SerafiniLamanna, Ex Diagnostics | ||
| Felicia Williams, Independent Director | ||
| Catherine Sazdanoff, Independent Director | ||
| Julie Smith, Controller VP | ||
| John Rice, Independent Director | ||
| Richard Eberly, Executive VP and President of Meridian Life Science | ||
| John McIlwraith, Independent Director | ||
| Dwight Ellingwood, Director | ||
| Marviette Johnson, Vice President - Human Resources | ||
| Vecheslav Elagin, Executive VP of RandD | ||
| John Kenny, CEO, Director | ||
| David Phillips, Independent Director | ||
| Andrew Kitzmiller, Ex CFO | ||
| Charles Wood, Bus Strategy | ||
| Jeff Pinkston, Director Fin | ||
| Marco Calzavara, President of Meridian Bioscience Europe and Managing Director of Meridian Bioscience Europe | ||
| Melissa Lueke, CFO, Executive VP and Secretary |
Meridian Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Meridian Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 43.83 M | |||
| Shares Owned By Insiders | 1.34 % | |||
| Shares Owned By Institutions | 90.92 % | |||
| Number Of Shares Shorted | 4.24 M | |||
| Price To Earning | 19.81 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Meridian Stock
If you are still planning to invest in Meridian Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Meridian Bioscience's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |